

Press Release



Dr. Reddy's announces the Launch of Fenofibrate Capsules, USP 43 mg and 130 mg

Hyderabad, India, April 23, 2014

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Fenofibrate Capsules, USP 43 mg and 130 mg a therapeutic equivalent generic version of ANTARA® (fenofibrate) capsules, in the US market on April 22, 2014, approved by the United States Food & Drug Administration (USFDA).

The ANTARA® (fenofibrate) capsules brand and generic had U.S. sales of approximately \$74 Million MAT for the most recent twelve months ending in February 2014 according to IMS Health*.

Dr. Reddy's Fenofibrate capsules, USP 43 mg is available in bottle counts of 30 and 130 mg are available in bottle counts of 30 and 90.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com

ANTARA® is a registered trademark of LUPIN ATLANTIS HOLDINGS, S.A. CORPORATION

*IMS National Sales Perspectives: Retail and Non-Retail MAT February 2014

For more information please contact:

Investors and Financial Analysts:

Kedar Upadhye at kedaru@drreddys.com /+91-40-66834297
Saunak Savla at saunaks@drreddys.com /+91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com / +1 609-375-9831

Media:

SVS Chowdary at chowdaryl@drreddys.com +91-40- 49002448

